BioGaia AB Interim Management Statement - January – June 2022
SECOND QUARTER 2022 · Net sales amounted to SEK 288.1 million (203.1), an increase of SEK 85.0 million, or 42% (excluding foreign exchange effects, 33%) of which the acquisition of Nutraceutics accounted for an increase of SEK 13.6 million (7%). Organic growth was 26%. · Net sales in the Paediatrics segment amounted to SEK 232.7 million (161.1), an increase of 44% (excluding foreign exchange effects, 34%). · Net sales in the Adult Health segment amounted to SEK 54.2 million (40.9), an increase of 33% (excluding foreign exchange effects, 24%). · Operating expenses amounted to